Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.

"Conflicts of interest R.M. has nothing to disclose. A.G.G. has nothing to disclose. J.C. reports grants from Instituto de Salud Carlos III-Ministerio de Ciencia, Innovación y Universidades outside this work. R.d.M. reports grants from Fondo de Investigaciones Sanitarias out of this work. Personal fees and nonfinancial support from Janssen, ViiV and Gilead, all outside this work. C.B. has nothing to disclose. J.I.B. has received personal fees and grants from Gilead, personal fees from ViiV healthcare, MSD, and Janssen outside this work. E.V. has received financial compensation for participating in presentations and advisory boards, as well as grants to attend conferences by MSD, ViiV Healthcare, Janssen Cilag and Gilead Sciences, all outside this work. M.L.M. has served as a speaker for Janssen, BMS, ViiV, Abbvie, Gilead and MSD; as a consultant for Janssen, BMS and Abbvie and has received research funding from FIPSE 36465/03, FIPSE 36680/97-NEAT IG5 (LSHP-CT-2006-037570. R.M.S. has received personal fees from Gilead, ViiV, Merck, Thera Technologies and Janssen outside this work. V.M. has nothing to disclose. I.P.V. has received personal fees for his participation in advifory boards and symposiums from Gilead Sciences, ViiV Healthcare, Hanssen Cilag and MSD. IPV has also received grants from Gilead Sciences and Janssen Cilag, all outside this work. L.S. has nothing to disclose. J.G.G. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work. J.R.A. reports grants from Instituto de Salud Carlos III outside this work has received grants and personal fees from VIIV, Gilead, personal fees from Janssen, MSD, Alexa and TEVA outside this work. L.M.C. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work."

"Conflicts of interestR.M. has nothing to disclose. A.G.G. has nothing to disclose. J.C. reports grants from Instituto de Salud Carlos III-Ministerio de Ciencia, Innovación y Universidades outside this work. R.d.M. reports grants from Fondo de Investigaciones Sanitarias out of this work. Personal fees and nonfinancial support from Janssen, ViiV and Gilead, all outside this work. C.B. has nothing to disclose. J.I.B. has received personal fees and grants from Gilead, personal fees from ViiV healthcare, MSD, and Janssen outside this work. E.V. has received financial compensation for participating in presentations and advisory boards, as well as grants to attend conferences by MSD, ViiV Healthcare, Janssen Cilag and Gilead Sciences, all outside this work. M.L.M. has served as a speaker for Janssen, BMS, ViiV, Abbvie, Gilead and MSD; as a consultant for Janssen, BMS and Abbvie and has received research funding from FIPSE 36465/03, FIPSE 36680/97-NEAT IG5 (LSHP-CT-2006-037570. R.M.S. has received personal fees from Gilead, ViiV, Merck, Thera Technologies and Janssen outside this work. V.M. has nothing to disclose. I.P.V. has received personal fees for his participation in advifory boards and symposiums from Gilead Sciences, ViiV Healthcare, Hanssen Cilag and MSD. IPV has also received grants from Gilead Sciences and Janssen Cilag, all outside this work. L.S. has nothing to disclose. J.G.G. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work. J.R.A. reports grants from Instituto de Salud Carlos III outside this work has received grants and personal fees from VIIV, Gilead, personal fees from Janssen, MSD, Alexa and TEVA outside this work. L.M.C. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work. Conflicts of interestR.M. has nothing to disclose. A.G.G. has nothing to disclose. J.C. reports grants from Instituto de Salud Carlos III-Ministerio de Ciencia, Innovación y Universidades outside this work. R.d.M. reports grants from Fondo de Investigaciones Sanitarias out of this work. Personal fees and nonfinancial support from Janssen, ViiV and Gilead, all outside this work. C.B. has nothing to disclose. J.I.B. has received personal fees and grants from Gilead, personal fees from ViiV healthcare, MSD, and Janssen outside this work. E.V. has received financial compensation for participating in presentations and advisory boards, as well as grants to attend conferences by MSD, ViiV Healthcare, Janssen Cilag and Gilead Sciences, all outside this work. M.L.M. has served as a speaker for Janssen, BMS, ViiV, Abbvie, Gilead and MSD; as a consultant for Janssen, BMS and Abbvie and has received research funding from FIPSE 36465/03, FIPSE 36680/97-NEAT IG5 (LSHP-CT-2006-037570. R.M.S. has received personal fees from Gilead, ViiV, Merck, Thera Technologies and Janssen outside this work. V.M. has nothing to disclose. I.P.V. has received personal fees for his participation in advifory boards and symposiums from Gilead Sciences, ViiV Healthcare, Hanssen Cilag and MSD. IPV has also received grants from Gilead Sciences and Janssen Cilag, all outside this work. L.S. has nothing to disclose. J.G.G. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work. J.R.A. reports grants from Instituto de Salud Carlos III outside this work has received grants and personal fees from VIIV, Gilead, personal fees from Janssen, MSD, Alexa and TEVA outside this work. L.M.C. has received personal fees from Gilead, ViiV, Merck, Janssen and Abbvie outside this work."